Are We Still Friends? What Brexit Means for UK Synthetic Biology
Synthetic biology is one of the big strengths of UK science, but can the country…
December 7, 2020 - 8 minutes
David Kirk
David Kirk is a freelance writer and communications consultant with interests in synthetic biology, biotech, and sustainability. He has a PhD in molecular microbiology and has industrial experience developing living medicines.
Artificial Intelligence: A Superpower in the Fight Against Covid-19
The rapid spread of Covid-19 around the world has left drug developers with limited time…
July 22, 2020 - 8 minutes
Chilean Biotech Moves to France to Develop Anti-Mold Food Preservative
The startup Protera is moving from Santiago de Chile to Paris following a €5M Series…
June 15, 2020 - 4 minutes
UK Startup Launches with €10M to Detect Epigenetic Signs of Cancer in Blood
A seed round of €10.1M will fund the launch of the University of Oxford spinout…
June 8, 2020 - 3 minutes
AI Drug Discovery Firm Exscientia Closes €54M Series C
UK-based Exscientia has closed a Series C financing round of €54M ($60M) to develop its…
May 29, 2020 - 3 minutes
Synthetic Biology Could Lead to Clean Energy Using Light and Carbon Dioxide
Researchers in Germany and France have combined synthetic biology with microfluidics to create artificial photosynthetic…
May 15, 2020 - 3 minutes
EU Pitches Into €7.4B Fund Supporting Covid-19 Treatments & Vaccines
The European Commission and global donors have pledged €7.4 billion to a fund aimed at…
May 7, 2020 - 4 minutes
AskBio Takes Over French Gene Therapy Company to Treat Alzheimer’s and Huntington’s
The Paris-based BrainVectis, a biotech developing gene therapies for Huntington’s disease and Alzheimer’s disease, has…
April 28, 2020 - 3 minutes
Anti-Aging Treatments at Forefront of Astellas’ €80M UK Acquisition
Japanese pharma giant Astellas has acquired the UK biotech Nanna Therapeutics for up to €80M…
April 28, 2020 - 3 minutes
UK Startup to Manufacture Cell and Gene Therapies with Microfluidics
The UK company MicrofluidX has closed a €1.6M (£1.4 M) seed funding round to develop…
April 24, 2020 - 3 minutes
Two European Alzheimer’s Disease Treatments Show Promise in Phase II
An epigenetics drug developed by the Spanish biopharmaceutical company Oryzon has reduced aggressive behavior in…
April 9, 2020 - 4 minutes
UK Biotech’s Arthritis Drug Enters Study in Coronavirus Patients
The UK company Izana Bioscience is freely providing its phase III-ready anti-inflammatory antibody namilumab in…
April 6, 2020 - 2 minutes
